FDA approves Endotronix Cordella PA sensor system for heart failure treatment

Endotronix today announced it received FDA premarket approval for its Cordella PA Sensor System.

The Naperville, Illinois=based company designed the Cordella Pulmonary Artery (PA) Sensor System to treat New York Heart Failure (NYHA) class III heart failure patients. It is the first PA pressure-guided platform to offer comprehensive patient management using daily PA pressure and vital signs from home to help guide therapeutic management.

“This approval is very exciting and has the potential to transform care for HF patients. Endotronix’s solution provides a more complete clinical picture of the patient, so providers are able to make informed remote care decisions between office visits,” said Dr. Liviu Klein, section chief of advanced heart failure, mechanical circulatory support, pulmonary hypertension and heart transplant at the University of California San Francisco.

Sign up for Blog Updates